Novartis AG
NOT
Company Profile
Business description
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Contact
Lichtstrasse 35
Basel4056
CHET: +41 613241111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,883
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 37.80 | -0.42% |
| CAC 40 | 8,170.75 | 40.75 | -0.50% |
| DAX 40 | 24,930.14 | 61.45 | 0.25% |
| Dow JONES (US) | 48,977.18 | 594.79 | 1.23% |
| FTSE 100 | 10,076.49 | 71.92 | 0.72% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,395.82 | 160.19 | 0.69% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,902.05 | 43.58 | 0.64% |
| S&P/ASX 200 | 8,682.80 | 45.80 | -0.52% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |